Clinical trials
Phase 2 Squamous Cell Carcinoma of Head and Neck trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 7 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 6 |
| Terminated | 6 |
| Active, not recruiting | 4 |
| Unknown status | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Gruppo Oncologico del Nord-Ovest | 3 |
| AstraZeneca | 2 |
| Gilead Sciences | 2 |
| ISA Pharmaceuticals | 2 |
| Kura Oncology, Inc. | 2 |
| Ascendis Pharma A/S | 1 |
| Bayer | 1 |
| BeiGene | 1 |
| CNAO National Center of Oncological Hadrontherapy | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Squamous Cell Carcinoma of Head and Neck | 34 |
| Head and Neck Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Squamous Cell | 4 |
| Recurrence | 4 |
| Esophageal Squamous Cell Carcinoma | 3 |
| Melanoma | 3 |
| Neoplasm Metastasis | 3 |
| Small Cell Lung Carcinoma | 2 |
| Uterine Cervical Neoplasms | 2 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.